Comparison 3. Exenatide 2 mg once weekly versus DPP‐4 inhibitors.
Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
---|---|---|---|---|
1 HbA1c (%) | 1 | Mean Difference (IV, Random, 95% CI) | Subtotals only | |
2 HbA1c < 7% | 1 | Risk Ratio (M‐H, Random, 95% CI) | Subtotals only | |
3 Hypoglycaemia (minor) | 1 | Risk Ratio (M‐H, Random, 95% CI) | Subtotals only | |
4 Weight change (kg) | 1 | Mean Difference (IV, Random, 95% CI) | Subtotals only | |
5 Quality of life | Other data | No numeric data | ||
6 Adverse events | Other data | No numeric data | ||
7 Blood pressure (mm Hg) | Other data | No numeric data | ||
8 Fasting plasma glucose (mmol/L) | 1 | Mean Difference (IV, Random, 95% CI) | Subtotals only | |
9 Post‐prandial glucose / glucose profiles | Other data | No numeric data | ||
10 Lipid profiles | Other data | No numeric data |